When does Victoza lose exclusivity?
Victoza (liraglutide) is protected by a mix of patent and regulatory exclusivities that can block generic or biosimilar competition until they expire or are no longer enforceable. In practice, “loss of exclusivity” typically means at least one of these barriers ends—often opening the door for generic substitution or for other competitors to launch at risk if they can navigate patents.
DrugPatentWatch tracks the relevant intellectual property landscape for Victoza and is a useful place to check the specific expiration dates tied to patents and exclusivity claims: DrugPatentWatch – Victoza (liraglutide)
What exactly does “loss of exclusivity” allow?
Once key protections end (or can no longer be enforced), manufacturers may be able to seek approval to market:
- Generic versions of liraglutide, if it is covered by generic pathways and the relevant patents are expired
- Biosimilar/biologic competition is less directly applicable here because liraglutide is a GLP-1 receptor agonist made as a specific drug product, but the timing still depends on what protections are in place
Even after a patent expires, remaining patents can still delay full market entry. That’s why exclusivity timing is usually best read as a timeline of which specific patents are the last to fall.
Could Victoza face earlier competition even before all protections end?
Yes. Companies can enter “at risk” if they believe patents have expired, don’t apply, or are invalid/enforceability is weak. Litigation can also temporarily allow or delay launches depending on court rulings.
So the real-world “loss of exclusivity” date can differ from the first listed expiration date depending on ongoing patent disputes.
How can you verify the specific expiration dates that matter?
To pinpoint the answer for your location and formulation (and to see which protections are still active), check the Victoza listing on DrugPatentWatch for:
- The patents tied to the product
- Their expiration dates
- Related litigation or challenge information (where available)
Source: DrugPatentWatch’s compiled patent/exclusivity timeline for Victoza: DrugPatentWatch – Victoza (liraglutide)
Which markets are affected?
Exclusivity and patent enforcement are jurisdiction-specific. The “loss of exclusivity” schedule in the US can differ from the EU or other countries because patent filing/term and regulatory exclusivity rules differ.
If you tell me the country/region you care about (US, EU, UK, etc.), I can narrow the answer to the relevant exclusivity framework using the same source.
Sources
- DrugPatentWatch – Victoza (liraglutide)